by Dr. Ed Weber | Feb 7, 2019 | PCa Commentary
Enzalutamide (ENZ) was reviewed in the PCa Commentary of March/April 2014. Many important developments have taken place since then. This Commentary will discuss the current indications for ENZ and new studies of ENZ as monotherapy. A subsequent Commentary will address... by Dr. Ed Weber | Feb 6, 2019 | PCa Commentary
This Commentary benefitted from a review and suggestions from Thomas Hope, MD, Associate Professor of Abdominal Imaging and Nuclear Medicine, UCSF THE FIRST QUESTION likely, is why present a Commentary about the Gallium68-PSMA-11 PET/CT scan. Its... by Dr. Ed Weber | Dec 6, 2018 | PCa Commentary
It has been one year since the Commentary featured the Axumin PET/CT in the November 2017 issue [control+click link to follow]. A great deal of new research about this scan performance has been published since then. The material in this issue is based on this... by Dr. Ed Weber | Nov 2, 2018 | PCa Commentary
Harnessing our immune system to treat cancer has been an elusive goal for decades. Research in immunotherapy is intense with active study of the newest advances, i.e. checkpoint inhibitors and CAR T cell technology. Checkpoint inhibitors have yielded encouraging... by Dr. Ed Weber | Oct 7, 2018 | PCa Commentary
The conventional National Cooperative Cancer Network (NCCN) risk categories — low-, intermediate-, and high-risk are largely based on the Gleason score as determined by the microscopic appearance of cells and their organization. However, beneath the surface appearance... by Dr. Ed Weber | Sep 6, 2018 | PCa Commentary
Many of the important adverse effects associated with androgen suppression with Lupron, Firmagon, or orchiectomy result from estrogen deficiency. Estimates vary, but 50%, 75%, or as much as 80% of a man’s serum estrogen arises from enzymatic conversion of serum...